DNAFORM was established in September 1998 as part of the venture business promotion program of the Institute of Physical and Chemical Research ("RIKEN"). DNAFORM's technology platform has been developed at Dr. Yoshihide Hayashizaki's laboratory at the RIKEN Omics Sciences Center, who is also the founder of DNAFORM.
Current business activities:
No.1 Business and Marketing Division (Clone related Operation)
1. Full-length cDNA Library preparation & genome functional annotation service etc
2. RIKEN FANTOM clone distribution and sublicensing activities
3. The Fantom Clone DNABook and printing-on-demand services
4. Manufacturing and marketing of reagents for molecular biology
|
No.2 Business and Marketing Division (SmartAmp Process related Operation)
1. Licensing and diffusion of Smart Amplification Process (SmartAmp) method as advanced genetic detection assay technology
2. Manufacturing and marketing of genetic detection assays reagent for SmartAmp
|
DNAFORM has worked closely together with RIKEN for the development of innovative technologies for transcriptome analysis and novel applications in detection.
Besides working closely together with RIKEN, DNAFORM uses its long-standing experience in the field to running its own in-house R&D program for developing proprietary technologies for innovative top quality products. As our mission, DNAFORM wants to be a leading company that contributes to improved living standards and health care.
DNAFORM Group
|
Kabushiki Kaisha DNAFORM
(Corporate under the law of Japan)
Affiliated Company
|
|
Kabushiki Kaisha DNAFORM
Starting capital: | 55.55 M JPY |
Role: |
-Management and Corporate Planning for DNAFORM group
-Manufacturing and marketing of SmartAmp related products and services
-Marketing of clone related products and services |
|
|
|
|
DNAFORM, Inc.
(Corporate under the law of USA)
Shareholder
|
DNAFORM , Inc.
Starting capital: | 43,397.50 US$ |
Role: |
-Manufacturing and Development of Clone related Business
-Overseas Promotion of SmartAmp related business |
|
|
|
|
|
Five Prime Therapeutics, Inc.
(Corporate under the law of USA)
|
Five Prime Therapeutics, Inc.
Business activity: | -novel applications in therapy human cDNA |
|
|
April 1, 2007
|
